Teva Pharmaceutical Indus Bolsa (NYSE: TEVA)

Teva Pharmaceutical Indus (NYSE:TEVA) Bolsa

Teva Pharmaceutical Indus

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Equities

News

Markets

Tech

General

ADBE

ADSK

AMZN

AVGO

GOOGL

MSFT

NTRA

NVDA

SBUX

TEVA

TSLA

Stanley Druckenmiller vendió todas sus acciones en Broadcom tras su alza del 100% y reforzó su inversión en grandes tecnológicas.

El nuevo giro de Druckenmiller: vende Broadcom y amplía su apuesta en tecnológicas clave

WIIM

AMRX

BHVN

CAPR

QURE

RCKT

REPL

SPRO

SRPT

Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.

Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) reported its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46716697/tevas-innovative-portfolio-fuels-10th-consecutive-quarter-of-growth-in-q2-2025-increases-2025-reve" rel="noreferrer noopener">second-quarter 2025</a> financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy.
The company reported total revenue of $4.20 billion, falling short of analysts&#8217; expectations of $4.29 billion, according to <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>. This marks a flat year-over-year result in U.S. dollars, with a slight decline of 1% in local currency terms.
The revenue shortfall was primarily driven by weaker sales in Teva&#8217;s generic drug portfolio. Specifically, the decline in generic revenues from its International Markets segment, compounded by the divestment of its Japanese business and a drop in sales from Copaxone, weighed on overall results.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/07/46701886/generic-revlimid-fades-but-tevas-broader-generics-outlook-remains-strong" rel="noreferrer noopener">Generic Revlimid Fades, But Teva&#8217;s Broader Generics Outlook Remains Strong</a>
However, these declines were partially offset by strong sales growth from Teva&#8217;s innovative drug offerings, including Austedo, Uzedy, and Ajovy.
Sales of Copaxone, a key multiple sclerosis treatment, fell by 23%, contributing just $62 million in revenue for the quarter. On a more positive note, Teva&#8217;s innovative portfolio saw impressive growth.
Austedo, an FDA-approved treatment for tardive dyskinesia, saw a 19% increase in sales, reaching $498 million. Uzedy, used in the treatment of schizophrenia, more than doubled its sales, totaling $54 million. Similarly, Ajovy, a migraine treatment, reported a 31% year-over-year increase, bringing in $155 million.
Teva&#8217;s generic segment showed stable performance overall. Global generics revenues declined by 2% in local currency, excluding Japan&#8217;s business venture, while U.S. generics saw a 6% drop. In contrast, European generics grew by 1%, and revenues from the International Markets segment fell by 1%.
Teva also reported strong growth in its biosimilars segment. The company attributed this to the robust performance of both existing and newly launched biosimilars. Teva expects this segment to continue growing, with plans to launch two new biosimilars in the second half of 2025. The company is on track to double biosimilars revenues from 2024 to 2027, underscoring its commitment to expanding its portfolio in this rapidly growing sector.
For the second quarter, Teva reported adjusted earnings of 66 cents per share, surpassing <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">analyst estimates of 62 cents per share</a>. The adjusted gross profit margin for the quarter improved to 54.6%, compared to 52.9% in the same period last year, reflecting the favorable mix of higher-margin innovative products.
Teva&#8217;s President and CEO, Richard Francis, highlighted the company&#8217;s growing portfolio as a key driver of its financial performance. &#8220;Teva&#8217;s performance this quarter stands as a testament to the exceptional strength of our innovative portfolio, which remains the primary engine driving our revenue growth,&#8221; Francis said. &#8220;Our key innovative products delivered a 26% increase in local currency, demonstrating their impact on our financial trajectory and value to patients.&#8221;
During the earnings conference call, Francis stated that 70% of Teva&#8217;s generics business operates outside the U.S., while its most innovative business is U.S.-based. On the supply chain, Teva has no reliance on China and a very small presence in India.
Teva&#8217;s CFO Eli Kalif confirmed that U.S. tariffs are absorbed into their 2025 non-GAAP outlook, indicating proactive financial planning to manage these impacts.
<h2 class="wp-block-heading">Outlook</h2>
Teva Pharmaceutical narrowed its fiscal 2025 adjusted earnings guidance to a range of $2.50-$2.60 per share from $2.45-$2.65 per share, slightly below the consensus estimate of $2.53.
The company also reaffirmed its full-year sales guidance of $16.8 billion-$17.2 billion, slightly lower than the consensus expectation of $17.01 billion.
This outlook takes into account the potential impact of tariffs and trade uncertainties within the pharmaceutical sector.
Teva raised its sales outlook for several key products. The sales forecast for Austedo in 2025 was increased to between $2 billion and $2.05 billion, up from the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" rel="noreferrer noopener">prior estimate of $1.95-$2.05 billion</a>.
Similarly, the company now expects Ajovy sales to reach $630 million-$640 million, surpassing its earlier guidance of $600 million.
Sales expectations for Uzedy were also raised from approximately $160 million to a range of $190-$200 million. Teva also expects around $370 million in sales from Copaxone in 2025.
For its operating income and adjusted EBITDA, Teva reaffirmed its guidance range of $4.3 billion-$4.6 billion and $4.7 billion-$5 billion, respectively.
The company remains focused on executing its long-term strategy, which includes building a $5 billion innovative medicines franchise by 2030, supported by its key assets and <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45678673/teva-reaffirms-growth-strategy-eyes-5-billion-innovative-franchise-by-2030" rel="noreferrer noopener">promising late-stage pipeline</a>.
As the company continues its pivot toward innovative therapies, it remains to be seen how it will navigate potential headwinds, including tariff impacts and competition in both its generic and biosimilar segments.
Price Action: TEVA stock is trading higher by 2.36% to $16.94 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46725904/unitedhealth-prognosis-mixed-analysts-trim-targets-but-keep-faith-after-q2-miss" target="_blank" rel="noreferrer noopener">UnitedHealth Prognosis Mixed: Analysts Trim Targets But Keep Faith After Q2 Miss</a></li>
</ul>
Photo via Shutterstock

Earnings

Large Cap

Guidance

Health Care

Movers

Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy

U.S. stocks inched higher midday Wednesday, as investors digested upbeat economic data while keeping an optimistic tone ahead of the Federal Reserve's policy decision and a wave of key tech earnings <a href="https://www.benzinga.com/markets/earnings/25/07/46693997/wall-street-earnings-preview-microsoft-apple-meta-amazon-mastercard-visa">due after the bell. </a>
<ul class="wp-block-list">
<li>The QQQ ETF is on track for a fourth consecutive monthly gain. <a href="https://www.benzinga.com/quote/QQQ">See the chart here.</a></li>
</ul>
The S&amp;P 500 rose 0.2%, the Nasdaq added 0.4%, and the Dow Jones hovered near the flatline. Small-cap stocks outperformed, with the Russell 2000 up 0.6%. 
Markets widely expect the Federal Reserve to keep rates steady at 4.25%-4.50%, but with two policymakers already showing preference for a cut, the decision could mark the most divided vote since 1993.
On the trade front, former President Donald Trump announced a new 25% tariff on Indian imports, set to take effect Aug. 1. 
Advance GDP data showed the U.S. economy grew at an annualized 3.0% in the second quarter of 2025, a sharp rebound from the previous quarter's 0.5% contraction and well above the 2.4% consensus, powered by strong consumer spending and a decline in imports. 
In the labor market, private payrolls rose by 104,000 in July, the strongest gain since March and a solid beat on the 75,000 forecast—reversing a contraction in June. 
Commodities were in focus as WTI crude extended its rally, surging 1.5% on the day to hit $70 a barrel, driven by geopolitical tensions following Trump's new 10-day ultimatum to Russia over peace talks with Ukraine. The three-day gain now totals over 8%.
Gold slipped 1% to $3,290 per ounce as the U.S. dollar strengthened on the back of robust economic data. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady around $118,000.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,257.27</td>
<td>0.6%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>23,396.45</td>
<td>0.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,384.59</td>
<td>0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,654.85</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:05 p.m. ET</figcaption></figure>
According to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) inched 0.1% higher to $584.81.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) flattened at $446.50.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.3% to $569.07.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 0.7% to $224.19.</li>
<li>The&nbsp;Utilities&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 1%; the&nbsp;Energy&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1%.</li>
</ul>
<h2 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h2>
<ul class="wp-block-list">
<li>Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) climbed 2.3%, poised to break a seven-day losing streak, after JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) announced a partnership with the crypto exchange that will allow Chase credit card holders to fund their Coinbase wallets and purchase cryptocurrencies. </li>
<li>Stocks moving on earnings reports included: 
<ul class="wp-block-list">
<li>Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) up 0.8%</li>
<li>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) flat</li>
<li>Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) up 1.2%</li>
<li>Automatic Data Processing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) up 1.9%</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) up 0.7%</li>
<li>Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) up 2.0%</li>
<li>Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) down 7.8%</li>
<li>Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) down 6.0%</li>
<li>Illinois Tool Works Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) down 2.0%</li>
<li>Republic Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) down 5.0%</li>
<li>American Electric Power Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) up 3.8%</li>
<li>Vertiv Holdings Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) up 1.6%</li>
<li>Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) down 5.5%</li>
<li>Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) up 7.2%</li>
<li>Entergy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) up 3.2%</li>
<li>Verisk Analytics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) down 4.8%</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) up 2.3%</li>
<li>WEC Energy Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) up 0.5%</li>
<li>Tradeweb Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>) up 4.9%</li>
<li>GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) down 4.9%</li>
<li>Arch Capital Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) down 1.0%</li>
<li>Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) down 8.8%</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) up 7.4%</li>
<li>Expand Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPN#NASDAQ">EXPN</a>) up 5.1%</li>
<li>Smurfit Westrock plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMUR#NYSE">SMUR</a>) down 2.1%</li>
<li>PPG Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) down 4.9%</li>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) up 3.6%</li>
<li>Essex Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) down 4.7%</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) up 21.2%</li>
<li>Fortive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) up 0.9%</li>
</ul>
</li>
</ul>
<h2 class="wp-block-heading">Stocks slated to report earnings after the close:</h2>
<ul class="wp-block-list">
<li>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</li>
<li>American Water Works Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>)</li>
<li>Antero Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>)</li>
<li>AvalonBay Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>)</li>
<li>Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>)</li>
<li>C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>)</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)</li>
<li>Cognizant Technology Solutions Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>)</li>
<li>Confluent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>)</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)</li>
<li>eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>)</li>
<li>Equinix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>)</li>
<li>Everest Group, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>)</li>
<li>Extra Space Storage Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>)</li>
<li>F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>)</li>
<li>Fair Isaac Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>)</li>
<li>FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>)</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)</li>
<li>GFL Environmental Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>)</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>)</li>
<li>Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>)</li>
<li>Host Hotels &amp; Resorts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>)</li>
<li>Independence Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>)</li>
<li>Invitation Homes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>)</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>)</li>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>)</li>
<li>Mid-America Apartment Communities, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>)</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>)</li>
<li>Prudential Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>)</li>
<li>PTC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>)</li>
<li>QUALCOMM Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>)</li>
<li>The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>)</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>)</li>
<li>UDR, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>)</li>
<li>Ventas, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTR#NYSE">VTR</a>)</li>
<li>VICI Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>)</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</li>
</ul>
Now Read
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/07/46720292/us-gdp-q2-economy-us-trump-fed-interest-rates-dollar">US Economy Roars Back With 3% Growth, Handing Trump A Timely Victory </a></li>
</ul>
Image: Shutterstock

Macro Economic Events

Economics

ETFs

$BTC

ACGL

BKNG

CFLT

CHRW

COIN

CTSH

CVNA

SPDR Dow Jones Industrial Average ETF Trust

DXCM

EBAY

EQIX

EXPN

FFIV

FICO

GEHC

GRMN

HOLX

INVH

LRCX

MDLZ

ODFL

QCOM

SMUR

VICI

VRSK

Stocks Rise Ahead Of Fed Meeting, Oil Jumps To $70: What's Moving Markets Wednesday?

Global

During Conf Call, Teva Pharmaceuticals CEO Says 70% Of Teva's Generics Business Is Outside The United States But Most Innovative Business Is In The U.S.; On Supply Chain, Teva Does Not Have Reliance On China And Very Small In India

During Conf Call, Teva Pharmaceutical CFO Reportedly Says Confirmed U.S. Tariffs Are Absorbed Into 2025 Non-GAAP Outlook

Outlook for 2025 Non-GAAP Results
<figure class="table"> 
<table>
<tbody>
<tr>
<td>$ billions, except EPS or as noted</td>
<td colspan="2">January 2025 Outlook</td>
<td colspan="3">May 2025 Outlook</td>
<td>July 2025 Outlook</td>
</tr>
<tr>
<td>Revenues&#x2A;</td>
<td colspan="2">$16.8 - $17.4</td>
<td colspan="3">$16.8 - $17.2</td>
<td>$16.8 - $17.2</td>
</tr>
<tr>
<td>AUSTEDO ($m)&#x2A;</td>
<td colspan="2">1,900-2,050</td>
<td colspan="3">1,950-2,050</td>
<td>2,000-2,050</td>
</tr>
<tr>
<td>AJOVY ($m)&#x2A;</td>
<td colspan="2">~600</td>
<td colspan="3">~600</td>
<td>630-640</td>
</tr>
<tr>
<td>UZEDY ($m)&#x2A;</td>
<td colspan="2">~160</td>
<td colspan="3">~160</td>
<td>190-200</td>
</tr>
<tr>
<td>COPAXONE ($m)&#x2A;</td>
<td colspan="2">~370</td>
<td colspan="3">~370</td>
<td>~370</td>
</tr>
<tr>
<td>Operating Income</td>
<td colspan="2">4.1 - 4.6</td>
<td colspan="3">4.3 - 4.6</td>
<td>4.3 - 4.6</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td colspan="2">4.5 - 5.0</td>
<td colspan="3">4.7 - 5.0</td>
<td>4.7 - 5.0</td>
</tr>
<tr>
<td>Tax Rate</td>
<td colspan="2">15%-18%</td>
<td colspan="3">15%-18%</td>
<td>15%-18%</td>
</tr>
<tr>
<td>Finance Expenses</td>
<td colspan="2">~0.9</td>
<td colspan="3">~0.9</td>
<td>~0.9</td>
</tr>
<tr>
<td>Diluted EPS ($)</td>
<td colspan="2">2.35 - 2.65</td>
<td colspan="3">2.45 - 2.65</td>
<td>2.50 - 2.65</td>
</tr>
<tr>
<td>Free Cash Flow&#x2A;&#x2A;</td>
<td colspan="2">1.6 – 1.9</td>
<td colspan="3">1.6 – 1.9</td>
<td>1.6 – 1.9</td>
</tr>
<tr>
<td>CAPEX&#x2A;</td>
<td colspan="2">~0.5</td>
<td colspan="3">~0.5</td>
<td>~0.5</td>
</tr>
</tbody>
</table>
</figure>

Teva Pharmaceutical Indus Narrows FY2025 Adj EPS Guidance from $2.45-$2.65 to $2.50-$2.60 vs $2.53 Est; Affirms FY2025 Sales Guidance of $16.800B-$17.200B vs $17.007B Est

Teva Pharmaceutical Indus Q2 2025 Adj. EPS $0.66 Beats $0.62 Estimate, Sales $4.200B Miss $4.298B Estimate

ALGN

ALHC

ALKT

AMRN

AMSC

ANIK

APLD

ARCB

AWRE

AXTA

BBDO

BLCO

BLFY

BLKB

BSBR

BXMT

CGNX

CHEF

CHKP

CLMB

CLVT

CMCO

CNMD

CNXN

COCO

COMP

CPSH

CRTO

CTOS

New Oriental Education & Technology Group

ENTG

EOSE

ETSY

EVTC

EZPW

FBRT

FORM

FRGE

FVRR

Earnings Scheduled For July 30, 2025

Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) will release its second-quarter 2025 financial <a href="https://www.benzinga.com/topic/pharmaceuticals">results tomorrow, July 30</a>.
According to <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, the company expects to report second-quarter earnings of 62 cents, with sales of <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">around $4.29 billion</a>.
Teva&#8217;s generics business has rebounded. The company saw a 5% increase in revenue across regions. Its top-three global portfolio may yield five new product launches by 2027.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45820489/goldman-sachs-bullish-on-branded-drug-upside-at-teva-what-about-viatris" target="_blank" rel="noreferrer noopener">Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?</a>
According to Piper Sandler, generic Revlimid won't matter much to the business after this year due to rising competition. However, it still plays a vital role in the U.S. generics segment.
The company's management expects the first quarter of 2025 to show the strongest year-over-year growth for its generics business.
They also noted that they usually sell most of their allowed amount of generic Revlimid in the second and third quarters.
Piper maintains an Overweight rating, increasing the <a target="_blank" href="https://www.benzinga.com/quote/TEVA/analyst-ratings" rel="noreferrer noopener">price forecast from $29 to $30</a>.
Additionally, settlements with other generic drugmakers will allow more competitors, including new ones, to enter the market and sell larger volumes in 2025.
Analyst David Amsellem questions whether total revenue for 2025 could be near the lower end of management's guidance <a href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" target="_blank" rel="noreferrer noopener">range of $16.8 billion-$17.2 billion</a>.
The analyst writes that since there is a possibility, Teva should not be penalized.
Austedo continues to grow steadily, with prescription volumes up approximately 19% year-to-date.
Uzedy is performing better than expected, with prescriptions increasing by about 21% in the second quarter of 2025 and 17% in the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" rel="noreferrer noopener">first quarter of 2025</a>.
Piper Sandler considers 2025 to be a low point for EBITDA, as cost-saving measures and efficiency improvements are expected to start benefiting profits in 2026.
Teva's branded drug business will also become more influential. A long-acting injectable version of olanzapine is launching in late 2026. It expects duvakitug by the end of the decade. And a $5 billion innovative medicines <a href="https://www.benzinga.com/general/biotech/25/05/45678673/teva-reaffirms-growth-strategy-eyes-5-billion-innovative-franchise-by-2030">franchise should be up and running by 2030</a>.
Additionally, Teva won't face major loss of exclusivity (LOE) issues until well into the 2030s. This supports the case for a higher valuation multiple.
Price Action: TEVA stock is down 0.09% at $16.50 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/07/46686877/drug-prices-to-get-more-expensive-under-trumps-eu-trade-deal-as-pharma-faces-billions-in-added-costs-report" target="_blank" rel="noreferrer noopener">Drug Prices To Get &#8216;More Expensive&#8217; Under Trump&#8217;s EU Trade Deal As Pharma Faces Billions In Added Costs</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Analyst Ratings

Trading Ideas

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-07-30. Here's what investors need to know before the announcement.
Analysts estimate that Teva Pharmaceutical Indus will report an earnings per share (EPS) of $0.61. 
The market awaits Teva Pharmaceutical Indus's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.06, leading to a 2.67% increase in the share price on the subsequent day.
Here's a look at Teva Pharmaceutical Indus's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.46</td>
<td>0.70</td>
<td>0.66</td>
<td>0.55</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.52</td>
<td>0.71</td>
<td>0.69</td>
<td>0.61</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-4.0%</td>
<td>0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753808549_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Teva Pharmaceutical Indus were trading at $16.51 as of July 28. Over the last 52-week period, shares are down 5.74%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analysts' Take on Teva Pharmaceutical Indus</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Teva Pharmaceutical Indus.
A total of 5 analyst ratings have been received for Teva Pharmaceutical Indus, with the consensus rating being Buy. The average one-year price target stands at $23.4, suggesting a potential 41.73% upside.
<h3>Analyzing Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Viatris, Corcept Therapeutics and Elanco Animal Health, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Viatris, with an average 1-year price target of $10.0, suggesting a potential 39.43% downside.</li>
<li>Analysts currently favor an Buy trajectory for Corcept Therapeutics, with an average 1-year price target of $145.0, suggesting a potential 778.26% upside.</li>
<li>Analysts currently favor an Buy trajectory for Elanco Animal Health, with an average 1-year price target of $16.8, suggesting a potential 1.76% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Viatris, Corcept Therapeutics and Elanco Animal Health, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teva Pharmaceutical Indus</td>
<td>Buy</td>
<td>1.89%</td>
<td>$1.88B</td>
<td>3.68%</td>
</tr>
<tr>
<td>Viatris</td>
<td>Neutral</td>
<td>-11.17%</td>
<td>$1.16B</td>
<td>-17.74%</td>
</tr>
<tr>
<td>Corcept Therapeutics</td>
<td>Buy</td>
<td>7.09%</td>
<td>$154.81M</td>
<td>2.98%</td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td>Buy</td>
<td>-1.00%</td>
<td>$684M</td>
<td>1.08%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Teva Pharmaceutical Indus ranks highest in Revenue Growth among its peers. It also leads in Gross Profit. However, it ranks lowest in Return on Equity.
<h3>Delving into Teva Pharmaceutical Indus's Background</h3>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
<h3>Teva Pharmaceutical Indus's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Teva Pharmaceutical Indus's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 1.89%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teva Pharmaceutical Indus's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 5.5%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.68%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.55%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Teva Pharmaceutical Indus's debt-to-equity ratio surpasses industry norms, standing at 2.71. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/TEVA/earnings">To track all earnings releases for Teva Pharmaceutical Indus visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Teva Pharmaceutical Indus's Earnings Potential

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$270.00</td>
<td>$663.7K</td>
<td>1.8K</td>
<td>3.3K</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$72.50</td>
<td>$44.4K</td>
<td>6.5K</td>
<td>2.2K</td>
</tr>
<tr>
<td>JANX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$22.50</td>
<td>$89.6K</td>
<td>288</td>
<td>427</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$800.00</td>
<td>$45.5K</td>
<td>194</td>
<td>213</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$12.00</td>
<td>$56.2K</td>
<td>5.4K</td>
<td>130</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$70.00</td>
<td>$128.7K</td>
<td>1.3K</td>
<td>91</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/29/25</td>
<td>$59.00</td>
<td>$28.0K</td>
<td>2</td>
<td>56</td>
</tr>
<tr>
<td>BBIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$40.00</td>
<td>$28.1K</td>
<td>1.6K</td>
<td>42</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$340.00</td>
<td>$59.2K</td>
<td>170</td>
<td>31</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$360.00</td>
<td>$25.0K</td>
<td>159</td>
<td>23</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 185 day(s) on January 16, 2026. This event was a transfer of 299 contract(s) at a $270.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $663.7K, with a price of $2220.0 per contract. There were 1803 open contracts at this strike prior to today, and today 3308 contract(s) were bought and sold. 
• Regarding EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we observe a call option trade with bullish sentiment. It expires in 31 day(s) on August 15, 2025. Parties traded 67 contract(s) at a $72.50 strike. The total cost received by the writing party (or parties) was $44.4K, with a price of $664.0 per contract. There were 6508 open contracts at this strike prior to today, and today 2208 contract(s) were bought and sold. 
• Regarding JANX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>), we observe a put option trade with bearish sentiment. It expires in 31 day(s) on August 15, 2025. Parties traded 427 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $89.6K, with a price of $210.0 per contract. There were 288 open contracts at this strike prior to today, and today 427 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 10 day(s) on July 25, 2025. Parties traded 50 contract(s) at a $800.00 strike. The total cost received by the writing party (or parties) was $45.5K, with a price of $910.0 per contract. There were 194 open contracts at this strike prior to today, and today 213 contract(s) were bought and sold. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option trade with neutral sentiment. It expires in 66 day(s) on September 19, 2025. Parties traded 130 contract(s) at a $12.00 strike. The total cost received by the writing party (or parties) was $56.2K, with a price of $433.0 per contract. There were 5421 open contracts at this strike prior to today, and today 130 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 338 day(s) on June 18, 2026. Parties traded 132 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $128.7K, with a price of $975.0 per contract. There were 1300 open contracts at this strike prior to today, and today 91 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be neutral, expiring in 45 day(s) on August 29, 2025. This event was a transfer of 50 contract(s) at a $59.00 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $560.0 per contract. There were 2 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For BBIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>), we notice a call option sweep that happens to be neutral, expiring in 31 day(s) on August 15, 2025. This event was a transfer of 35 contract(s) at a $40.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $28.1K, with a price of $805.0 per contract. There were 1699 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with bullish sentiment. It expires in 549 day(s) on January 15, 2027. Parties traded 25 contract(s) at a $340.00 strike. The total cost received by the writing party (or parties) was $59.2K, with a price of $2370.0 per contract. There were 170 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
• Regarding HCA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), we observe a put option sweep with bullish sentiment. It expires in 66 day(s) on September 19, 2025. Parties traded 18 contract(s) at a $360.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $1390.0 per contract. There were 159 open contracts at this strike prior to today, and today 23 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BBIO

JANX

10 Health Care Stocks Whale Activity In Today's Session

Teva Pharmaceutical Indus's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) short percent of float has risen 11.82% since its last report. The company recently reported that it has 40.00 million shares sold short, which is 3.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.68 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Teva Pharmaceutical Indus Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752174030_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teva Pharmaceutical Indus has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teva Pharmaceutical Indus's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Teva Pharmaceutical Indus's peer group average for short interest as a percentage of float is 3.59%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Teva Pharmaceutical Indus's Recent Short Interest

<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf" title="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf</a>

FDA Says Manufacture Of Teva Pharmaceuticals' Eszopiclone, Tablet, 1 Mg, 2mg, 3mg Discontinued

In the preceding three months, 5 analysts have released ratings for Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $23.4, with a high estimate of $25.00 and a low estimate of $22.00. This upward trend is apparent, with the current average reflecting a 7.98% increase from the previous average price target of $21.67.
<img src="https://www.benzinga.com/files/images/story/2025/1750968052_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Teva Pharmaceutical Indus among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Teva Pharmaceutical Indus. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Teva Pharmaceutical Indus's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Teva Pharmaceutical Indus's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TEVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teva Pharmaceutical Indus analyst ratings.</a>
<h2>About Teva Pharmaceutical Indus</h2>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
<h3>A Deep Dive into Teva Pharmaceutical Indus's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Teva Pharmaceutical Indus displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 1.89%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Teva Pharmaceutical Indus's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.5%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Teva Pharmaceutical Indus's ROE stands out, surpassing industry averages. With an impressive ROE of 3.68%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Teva Pharmaceutical Indus's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.55%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Teva Pharmaceutical Indus's debt-to-equity ratio surpasses industry norms, standing at 2.71. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Teva Pharmaceutical Indus Stock

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy and lowers the price target from $24 to $23.

Price Target

UBS Maintains Buy on Teva Pharmaceutical Indus, Lowers Price Target to $23

<ul>
<li>Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki1,2</li>
<li>Fremanezumab demonstrated sustained effectiveness and a favourable safety and tolerability profile over the two-year study period1,2</li>
<li>Injection adherence remained high throughout the study (~90%), while over 75% of patients completed the study duration1</li>
</ul>

Teva's Final PEARL Study Data Confirm AJOVY's Sustained Migraine Prevention And Favorable Safety Over Two Years

EMA's CHMP Recommended Granting Marketing Authorization For Teva's Austedo For The Treatment Of Adults With Moderate-to-severe Tardive Dyskinesia

Goldman Sachs has initiated coverage of generic pharmaceutical stocks, highlighting the sector's strong long-term <a href="https://www.benzinga.com/general/health-care">potential despite recent volatility</a>. 
Analyst Matt Dellatorre points to a mix of company-specific challenges—such as fiscal 2025 guidance—and broader industry concerns like tariffs and drug pricing. 
Still, he argues that many of these stocks are attractively valued and represent businesses well-positioned for growth.
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45819356/dogecoin-down-10-on-the-week-is-the-musk-trump-spat-bearish-for-doge">Dogecoin Down 10% On The Week: Is The Musk-Trump Spat Bearish For DOGE?</a>
<h2 class="wp-block-heading">Teva Pharmaceutical </h2>
Goldman Sachs has initiated Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy rating, with a <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $24</a>. 
Dellatorre sees an improvement in the core business, with an upside to consensus EBITDA estimates driven by strong growth in the branded segment.
On the generics side, Goldman Sachs expects limited growth over the next few years as an expanding biosimilar portfolio. Other new product launches are offset by the Revlimid settlement expiration in 2026.
The analyst expects robust growth on continued momentum for key assets on the branded side, acknowledging the industry-wide Part D re-design hit to <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45260240/teva-shares-climb-on-profit-beat-700-million-cost-plan-biopharma-pivot-momentum" rel="noreferrer noopener">2025 growth and margins</a>.
Goldman views Teva&#8217;s biosimilar portfolio as an important long-term growth driver for the generics business. The company now has 10 in-line assets and 13 biosimilars in the pipeline. 2027 expects five potential launches in the U.S. and three in the EU/exUS.
Teva expects biosimilar revenue of around $400 million in fiscal 2024 to double by fiscal 2027.
Goldman writes that Teva&#8217;s branded pipeline represents a significant valuation lever. It sees a favorable catalyst path over the next 24 months. The analyst sees an attractive catalyst path, with multiple opportunities to re-rate as these pipeline assets are de-risked.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45297381/viatris-shares-positive-data-from-investigational-contraceptive-patch-fast-acting-meloxicam-reduces-opioid-use-in-surgery-pain-trials" rel="noreferrer noopener">Viatris Discloses Positive Data From 2 Drugs In Earnings Report, Stock Soars</a>
<h2 class="wp-block-heading">Viatris</h2>
Dellatorre initiated Viatris Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) with a Neutral rating and <a href="https://www.benzinga.com/quote/VTRS/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $10</a>. Why? There&#8217;s a lack of clarity on the growth outlook for the core business given current structural dynamics in the generics and branded segments.
More specifically, on the generics side, <a target="_blank" href="https://www.benzinga.com/25/05/45297381/viatris-shares-positive-data-from-investigational-contraceptive-patch-fast-acting-meloxicam-reduces-opioid-use-in-surgery-pain-trials" rel="noreferrer noopener">excluding Indore</a>, Goldman is optimistic about recent underlying trends and continues to monitor Viatris&#8217; ability to meaningfully offset price erosion via new product launches and progress on the ongoing portfolio optimization.
In the branded drugs segment, the analyst writes that older products losing market share in the U.S. and Asia have hurt growth, and it is watching for signs of recovery. However, there have been signs of stabilization in developed markets, China, and other emerging markets in recent quarters. Despite the decline, these products still generate steady cash, and Goldman is observing how the company reinvests this into new growth opportunities.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45175642/drug-maker-amneal-highlights-strong-commercial-uptake-for-parkinsons-drug-but-q1-earnings-are-mixed" rel="noreferrer noopener">Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson&#8217;s Drug But Q1 Earnings Are Mixed</a>
<h2 class="wp-block-heading">Amneal Pharmaceuticals&nbsp;</h2>
Goldman initiated Amneal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) with a Buy rating and a <a href="https://www.benzinga.com/quote/AMRX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $12</a>.
The analyst is optimistic about the growth outlook for Amneal&#8217;s core business. He cites a strong product pipeline and track record of execution through various market environments.
Goldman has confidence in Amneal&#8217;s ability to continue to offset typical price erosion via new product launches. Amneal also has structural tailwinds as the company aggressively shifts its focus toward higher-value products.
In the branded segment, analyst Dellatorre is positive on the ongoing launch of the next-generation <a target="_blank" href="https://www.benzinga.com/25/04/44673049/amneals-combination-drug-shows-improved-sleep-quality-in-parkinsons-disease-patients" rel="noreferrer noopener">Parkinson&#8217;s disease drug</a> Crexont to ultimately offset Rytary&#8217;s 2025 loss of exclusivity and the endocrinology franchise&#8217;s stable growth outlook.
Price Action: TEVA stock is up 1.39% at $17.49, AMRX stock is up 2.37% at $7.34, and VTRS stock is up 2.07% at $8.64 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45800081/dr-reddys-and-alvotech-join-hands-to-develop-biosimilar-for-mercks-blockbuster-cancer-drug" target="_blank" rel="noreferrer noopener">Dr Reddy&#8217;s And Alvotech Join Hands To Develop Biosimilar For Merck&#8217;s Blockbuster Cancer Drug</a></li>
</ul>
Image: Shutterstock

Initiation

VTRS

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

Goldman Sachs analyst Matt Dellatorre initiates coverage on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy rating and announces Price Target of $24.

Goldman Sachs Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $24

Teva Pharmaceutical Indus's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) short percent of float has risen 36.14% since its last report. The company recently reported that it has 38.70 million shares sold short, which is 3.39% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Teva Pharmaceutical Indus Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749128429_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teva Pharmaceutical Indus has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teva Pharmaceutical Indus's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Teva Pharmaceutical Indus's peer group average for short interest as a percentage of float is 3.58%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Teva Pharmaceutical Indus?

Press Releases

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

IPOs

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Small Cap

Opinion

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

Teva Releases Q2 2025 Aide Memoire

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

Comments

Teva Pharmaceutical Indus

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL